ADAs Uncommon with STRIDE Regimen Himalaya analysis suggests ADAs don't impair response to tremelimumab or durvalumab in hepatocellular carcinoma
ADAs Uncommon with STRIDE Regimen Himalaya analysis suggests ADAs don't impair response to tremelimumab or durvalumab in hepatocellular carcinoma is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jan 23, 2023
Termination Date: Jan 22, 2024
Activity Goal:
The goal of this program is to provide data from medical meetings, expert analysis insights on current and emerging management strategies, and interactive case studies based on the most up-to-date evidence-based medicine and clinical trial results in HCC.
Learning Objective(s):
• Evaluate the latest clinical trial data regarding novel tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), anti-vascular endothelial growth factor (VEGF) agents, and emerging
combinations for the treatment of advanced HCC.
• Create individualized treatment plans for advanced HCC by utilizing updated clinical guidelines to advance care.
Additional details will be posted as soon as information is available.